Growth Hormone Secretagogues: GHS-R1a and GHRH Pathway Research

Growth hormone secretagogues represent a class of research compounds that stimulate endogenous growth hormone release through receptor-specific mechanisms. AUREX offers two complementary secretagogue compounds — AX-03 (Performance I) targeting GHS-R1a and AX-04 (Performance II) targeting the GHRH receptor — each with distinct pharmacological profiles and research applications.

AX-03 (Performance I) — GHS-R1a Agonism: AX-03 binds the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein coupled receptor predominantly expressed in the anterior pituitary and hypothalamus. Activation triggers pulsatile growth hormone release through a ghrelin-mimetic mechanism distinct from the GHRH axis. Published preclinical data demonstrates sustained IGF-1 elevation without the receptor desensitization observed with continuous GH administration, making AX-03 a staple in performance-oriented research protocols.

AX-03 Research Applications: Key published findings include dose-dependent growth hormone pulse amplification (2-5x baseline in preclinical models), sustained IGF-1 elevation over 8-12 week protocols, increased lean body mass indices in animal models, enhanced bone mineral density markers, improved sleep architecture (increased slow-wave sleep duration), and appetite stimulation through peripheral ghrelin-pathway activation. AX-03 is priced at $64.99 for 10mg with ≥99% verified purity.

AX-04 (Performance II) — GHRH Pathway: AX-04 operates through the growth hormone releasing hormone receptor, a distinct signaling axis from GHS-R1a. The compound features a modified structure that extends biological half-life compared to native GHRH, allowing for sustained receptor activation. Preclinical models show clean pulsatile GH release patterns without the appetite stimulation associated with GHS-R1a agonists.

Complementary Mechanisms: Research groups investigating combined AX-03 + AX-04 protocols report synergistic GH release exceeding either compound alone. The rationale: GHS-R1a and GHRH receptors converge on different intracellular signaling cascades (Gq/11 vs Gs) that amplify anterior pituitary somatotroph output when activated simultaneously. This dual-pathway approach is among the most published combination protocols in secretagogue research.

Important Research Considerations: Growth hormone secretagogues produce pulsatile, not continuous, GH elevation — this is a critical distinction from exogenous GH administration. Pulsatile release maintains physiological feedback mechanisms and avoids the receptor downregulation associated with continuous GH exposure. Timing of administration matters: preclinical data suggests optimal GH pulse amplitude when compounds are administered during fasting states or pre-sleep, when endogenous somatostatin tone is lowest.

All AUREX performance compounds are manufactured via Fmoc solid-phase synthesis in cGMP-compliant US facilities and independently verified by third-party HPLC-MS analysis. Certificates of Analysis are published for every batch.